DDrare: Database of Drug Development for Rare Diseases

Fremanezumab (DrugBank: Fremanezumab)

2 diseases

ID	Disease name (Link within this page)	Number of trials
124	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	1
226	Interstitial cystitis with Hunners ulcer	1

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [ 11 clinical trials, 13 drugs, (DrugBank: 4 drugs), 3 drug target genes, 11 drug target pathways]

Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 11 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04334408 (ClinicalTrials.gov)	January 2021	2/4/2020	Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL	A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL	Cadasil;Migraine	Drug: Fremanezumab;Drug: Placebo	Mayo Clinic	NULL	Not yet recruiting	18 Years	70 Years	All	5	Phase 2	United States

226. Interstitial cystitis with Hunners ulcer [ 133 clinical trials, 151 drugs, (DrugBank: 46 drugs), 48 drug target genes, 137 drug target pathways]

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 133 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04447729 (ClinicalTrials.gov)	October 15, 2020	10/6/2020	A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome	A Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Female Patients With Interstitial Cystitis-Bladder Pain Syndrome	Interstitial Cystitis	Drug: fremanezumab	Teva Branded Pharmaceutical Products R&D, Inc.	NULL	Withdrawn	18 Years	N/A	Female	0	Phase 2	NULL